A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
Latest Information Update: 20 Sep 2024
At a glance
- Drugs ZN d5 (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors K-Group Alpha
Most Recent Events
- 13 Sep 2024 Status changed from active, no longer recruiting to completed.
- 12 Apr 2024 This trial has been completed in Greece (End Date: 14 Feb 2024), according to European Clinical Trials Database record.
- 17 Mar 2024 This study has been Completed in Cyprus, According to European Clinical Trials Database record.